In 2009, GlaxoSmithkline and Pfizer formed a new joint venture, ViiV, to pursue AIDs therapeutics. ViiV Healthcare is majority owned by GSK and signifies the collaboration of the two companies' HIV/AIDS operations into a new business. Now the time may be near where the companies might spin this off in an IPO - depending mainly on how the drugs in its pipeline perform n the clinics.
Speaking at the Reuters Health Summit on Tuesday, Glaxo Chief Strategy Officer David Redfern said: "If it becomes clear to GSK and Pfizer that giving the company even more independence and its own access to the capital markets makes sense, then we would be very open to doing that."
GSK says it is also open to pursuing more of these type of joint arrangements in other therapeutic areas. If succesful, GSK could push more projects into this type of model. See in-Pharma Technologist.com.
Posted by Bruce Lehr November 16th 2010.